Takeaway
- Kidney stone formers (SFs) have an increased risk of developing metabolic syndrome (MetS), particularly those with calcium oxalate and uric acid stones.
Why this matters
- Findings warrant routine assessment for components of MetS when assessing kidney SFs, given the further risk of kidney stone disease and the long-term cardiovascular implications.
Study design
- This comparative cohort study included 828 kidney SFs referred to a metabolic centre in Southern England and 2484 age- and sex-matched non-SF comparators (control group) with a median follow-up of 19 years.
- MetS was defined as per the modified Association of American Clinical Endocrinologists criteria.
- Funding: None disclosed.
Key results
- Kidney SFs vs control individuals had a significantly increased risk of MetS (43.6% vs 24.8%; adjusted HR [aHR], 1.77; 95% CI, 1.55-2.03; P<.001).
- This association remained robust after adjustment for the presence of previous components of MetS (aHR, 1.91; 95% CI, 1.66-2.19; P<.001).
- This effect was consistent with sub-analyses of no previous components of MetS (aHR, 1.98; 95% CI, 1.69-2.31; P<.001) and 1 or 2 previous components of MetS (aHR, 1.54; 95% CI, 1.11-2.14; P=.011).
- Sub-analyses of stone types demonstrated that patients with calcium oxalate stones (aHR, 1.82; 95% CI, 1.53-2.16; P<.001) and urate stones (aHR, 3.87; 95% CI, 2.23-6.72; P<.001) had an increased risk of MetS.
- Other stone types were not linked with a significantly increased risk of MetS.
Limitations
- Risk of under-ascertainment of MetS at baseline.
This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.
